Skip to content
Screener

Net Change in Cash at other companies

Schrodinger logo
SchrodingerSDGR
$25.2M
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$26.13M-135%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$108.36M-539%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$16.65M+84.0%
Absci Corporation logo
Absci CorporationABSI
-$11.39M-293%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$60.3M+173%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.99B+62.2%
Enterprise value$1.98B+58.2%
P/S30.1×-7.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001703057-26-000028
Line itemThree months ended March 31, 2025Three months ended March 31, 2026
Proceeds from long-term liabilities and other5,9707,192
Net cash provided by financing activities5,9707,192
Effect of exchange rate changes on cash and cash equivalents590(38)
Increase (decrease) in cash and cash equivalents2,941(51,450)
Cash and cash equivalents and restricted cash, beginning of period183,615155,249
Cash and cash equivalents and restricted cash, end of period$186,556$103,799
Restricted cash included in other assets2,2901,736
Total cash, cash equivalents, and restricted cash shown on the balance sheet$184,266$102,063

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s net change in cash?
AbCellera Biologics Inc. (ABCL) reported net change in cash of -$51.45M in Q1 2026.
How has AbCellera Biologics Inc.'s net change in cash changed year-over-year?
AbCellera Biologics Inc.'s net change in cash decreased by 1849.4% year-over-year, from $2.94M to -$51.45M.
What is the long-term trend for AbCellera Biologics Inc.'s net change in cash?
Over 2 years (2021 to 2024), AbCellera Biologics Inc.'s net change in cash has grown at a -50.3% compound annual growth rate (CAGR), from -$92.97M to $23.01M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about AbCellera Biologics Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude